Abstracts tagged "Outcome measures"

Abstract Number: 0583 • ACR Convergence 2024
Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
Alexis Ogdie¹, Philip Mease², Francois Nantel³, Frederic Lavie⁴, Mohamed Sharaf⁵, Emmanouil Rampakakis⁶, Helena Marzo-Ortega⁷ and Laure Gossec⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ³Nantel MedSci Consult, Montreal, QC, Canada, ⁴Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁵Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁸Sorbonne Université, Paris, France
Background/Purpose: PsA disease activity (DA) and impact on patients (pts) are measured with clinical and pt-reported outcomes1. Minimal clinically important improvement (MCII), the smallest improvement…
Abstract Number: 0682 • ACR Convergence 2024
Results from Outcomes Selection and Development of a Patient-reported Outcome Measure for a Combined Response Index for Limited Cutaneous SSc: The CRISTAL Project
Alain Lescoat¹, Yen Chen², Susan Murphy³, Nadia Vann², Neda Kortam², Rosemary Gedert², Sue Farrington⁴, Yannick Allanore⁵, David Cella⁶, Lorinda Chung⁷, Philip Clements⁸, Christopher Denton⁹, Francesco Del Galdo¹⁰, Oliver Distler¹¹, Monique Hinchcliff¹², Michael Hughes¹³, Laura Hummers¹⁴, John Pauling¹⁵, Janet Pope¹⁶, Virginia Steen¹⁷, John Varga², Peter Merkel¹⁸, Maya H. Buch¹⁹ and Dinesh Khanna², and all CRISTAL collaborators, ¹CHU Rennes - University Rennes 1, Rennes, France, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Plymouth, MI, ⁴Scleroderma & Raynaud UK, London, United Kingdom, ⁵Université Paris Cité, Paris, France, ⁶Northwestern University, Chicago, IL, ⁷Stanford University, Woodside, CA, ⁸United States, Los Angeles, CA, ⁹University College London, Northwood, United Kingdom, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ¹²Yale School of Medicine, Westport, CT, ¹³Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ¹⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ¹⁵North Bristol NHS Trust, Bristol, United Kingdom, ¹⁶University of Western Ontario, London, ON, Canada, ¹⁷Georgetown University School of Medicine, Washington, DC, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures available to assess symptoms…
Abstract Number: 1027 • ACR Convergence 2024
Evaluation of Health Disparities in Outcomes of Patients with Juvenile Idiopathic Arthritis
Julia Harris¹, Jade Singleton² and Sheetal Vora³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Seattle Children's Hospital, Seattle, ³Atrium Health Levine Children's Hospital, Charlotte, NC
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease complicated by significant morbidity and disability with suboptimal rates of prolonged remission, decreased health-related quality…
Abstract Number: 1333 • ACR Convergence 2024
Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study
Orit Schieir¹, Marie-France Valois², Gilles Boire³, Louis Bessette⁴, Carter Thorne⁵, Susan Bartlett², Glen Hazlewood⁶, Carol Hitchon⁷, Diane Tin⁵, Hugues Allard-Chamard⁸, Bindee Kuriya⁹, Janet Pope¹⁰ and Vivian Bykerk¹¹, and on behalf of CATCH Investigators, ¹McGill University, Montreal, QC, Canada, ²Centre for Outcomes Research & Eval, Montreal, QC, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴University of Laval, Quebec City, QC, Canada, ⁵Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Toronto, Toronto, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Hospital For Special Surgery, New York, NY
Background/Purpose: Despite advances in early RA diagnosis and therapies, treatment outcomes can still vary considerably. Our objective was to compare short and long-term disease control…
Abstract Number: 1558 • ACR Convergence 2024
Mapping in Healthy Subjects Different Body Areas for Dermal Thickness and Skin Hardness by High Frequency Sonography and Durometry
Maurizio Cutolo¹, Elvis Hysa², Nathalie Berghen³, Tessa Dufour⁴, Andrea Cere⁵, Kaat Wyckstandt³, Emanuele Gotelli¹ and vanessa smith⁶, ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ³University of Ghent, Ghent, Italy, ⁴University Hospital Ghent, Gent, Belgium, ⁵University of Ghent, Ghent, Belgium, ⁶Ghent University Hospital, Gent, Belgium
Background/Purpose: Skin involvement is a prominent feature of systemic sclerosis (SSc). The reliability of non-invasive tools such as high frequency skin ultrasound (HFSU) and durometry,…
Abstract Number: 2064 • ACR Convergence 2024
Quantifying Cutaneous Dermatomyositis: A Novel 3D Image-based Approach
Nantakarn Pongtarakulpanit¹, Tanya Chandra¹, shiri keret², Eugenia Gkiaouraki³, Vladimir Liarski¹, Dana Ascherman³, Siamak Mogahadam¹, Chester Oddis¹ and Rohit Aggarwal⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Rapid advancement in image analysis now has a critical role in the diagnosis and assessment of skin lesions. The current standard of visual examination…
Abstract Number: 2328 • ACR Convergence 2024
Do Patients That Develop PsA Before Psoriasis Have Different Disease Outcomes?
Fadi Kharouf¹, Virginia Carrizo Abarza², Shangyi Gao³, Daniel Pereira⁴, Richard Cook⁵, Vinod Chandran⁶ and Dafna Gladman⁷, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Waterloo, Waterloo, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Most patients with Psoriatic Arthritis (PsA) experience psoriasis (Ps) before the onset of arthritis. However, in about 15% of the cases, the skin and…
Abstract Number: 0132 • ACR Convergence 2024
Patients with Systemic Autoimmune Rheumatic Diseases Remain at Risk for Hospitalization for COVID-19 Infection in the Omicron Era (2022-2024): A Retrospective Cohort Study
Naomi Patel¹, Andrew King¹, Shruthi Srivatsan¹, Xiaosong Wang², Emily Kowalski³, Kathleen Vanni³, Grace Qian², Jennifer Hanberg³, Katarina Bade³, Alene Saavedra³, Kevin Mueller³, Zachary Williams¹, Colebrook Johnson¹, Madison Negron¹, Jeffrey Sparks⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of severe acute COVID-19 infection has substantially decreased since the start of the pandemic. However, the risk of severe acute COVID-19 outcomes…
Abstract Number: 0361 • ACR Convergence 2024
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Nada Alrifai¹, Anushree Puttur², Laith Alhuneafat³, Fares Ghanem⁴, yadhu Dhital², Ahmad Jabri⁵ and David Feinstein⁶, ¹Cooper University Hospital, Cherry Hill, NJ, ²Allegheny Health Network, Pittsburgh, PA, ³University of Minnesota, Minneapolis, MN, ⁴Southern Illinois University, Springfield, IL, ⁵Henry Ford, Detroit, MI, ⁶Cooper University, Camden, NJ
Background/Purpose: Autoimmune connective tissue diseases (CTD) predominantly affect women during their reproductive years. CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic…
Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Alexis Ogdie¹, Xiaolan Ye², Yi Peng³, Christopher Saffore⁴, Jayne Stigler⁵ and Martin Bergman⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶self, Beach Haven, NJ

Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…
Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 1032 • ACR Convergence 2024
Impact of a Coordinated Care Model for Addressing Rheumatoid Arthritis and Associated Comorbidities
Alexis Barbut¹, Marsha Jackson², Krista Kowiak², Julie McIntyre² and Allen Anandarajah¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester
Background/Purpose: Rheumatoid Arthritis (RA) is often associated with comorbidities including hypertension, cardiovascular disease, osteoporosis, lung disease, and eye involvement. Studies suggests that the average RA…
Abstract Number: 1341 • ACR Convergence 2024
Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis
Santiago Dans Caballero¹, Marta Rojas Giménez², Clementina López Medina³, Andrea Cid Chaves², Mónica Rico-Muñoz³, mitndbaim aelohim parra Moreno² and Alejandro Escudero-Contreras⁴, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory condition characterized by joint inflammation and systemic involvement. In this preliminary study, we explore the potential link…
Abstract Number: 1581 • ACR Convergence 2024
Neutrophil-to- lymphocyte Ratio: A Possible Biomarker for Clinical Response After Autologous Hematopoietic Stem Cell Transplantation
shiri keret¹, Lisa Kaly², Georg Schett³, Christina Bergmann⁴, Joerg Henes⁵, Gleb Slobodin² and Doron Rimar², ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁵University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Baseline high Neutrophil- to- lymphocyte ratio (NLR) (higher than 2.95) is associated with severe progressive skin and lung disease and with reduced 5-year survival…
Abstract Number: 2087 • ACR Convergence 2024
Association of MRI-Defined Structure Features at Baseline with Knee Pain and Function Trajectories: Data from the Osteoarthritis Initiative (OAI)
Shen Liu¹, Thang Doung², Yong Ge³, Xiaoxiao Sun⁴, Yvonne Golightly⁵, Amanda Nelson⁶, Tuhina Neogi⁷, Jeffery Duryea⁸ and Kent Kwoh⁹, and Osteoarthritis Initiative (OAI) and Pivotal Osteoarthritis MRI Analyses (POMA) investigators, ¹Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ²Department of Computer Science, University of Arizona College of Science, Tucson, AZ, ³Department of Information Sciences, Eller College of Manangement, University of Arizona, Tucson, AZ, ⁴Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹University of Arizona, Tucson, AZ
Background/Purpose: Characterizing knee symptom (i.e., pain and function) trajectories and understanding differences among symptom trajectories have the potential to promote the development of customized treatment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].